Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and Polycystic Kidney, Autosomal Dominant

rosiglitazone has been researched along with Polycystic Kidney, Autosomal Dominant in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fu, L; Liu, C; Mei, C; Yuan, L; Zhang, Y1
Fu, L; Gao, X; Li, H; Liu, C; Mei, C; Wang, X; Yang, M; Yuan, L1
Cai, H; Fu, L; Gao, X; Hu, H; Liu, C; Liu, M; Mei, C; Wang, X; Xiao, M; Xiong, X1
Dai, B; Fu, L; Jia, J; Liu, Y; Mei, C1
Dai, B; Fu, L; Hua, Z; Liu, Y; Mei, C; Xu, C1
Brookes, ZL; Huang, L; Nauli, SM; Ong, AC; Prasad, S; Ruff, L; Solanky, T; Upadhyay, VS1

Other Studies

6 other study(ies) available for rosiglitazone and Polycystic Kidney, Autosomal Dominant

ArticleYear
Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
    Molecular medicine reports, 2013, Volume: 8, Issue:3

    Topics: Animals; Cell Proliferation; Cells, Cultured; Epithelial Cells; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor I; Kidney Tubules; Mice; Phosphorylation; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Dominant; PPAR gamma; Ribosomal Protein S6 Kinases, 70-kDa; RNA Interference; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones

2013
Concomitant use of rapamycin and rosiglitazone delays the progression of polycystic kidney disease in Han:SPRD rats: a study of the mechanism of action.
    American journal of physiology. Renal physiology, 2018, 05-01, Volume: 314, Issue:5

    Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Epithelial Cells; Fibrosis; G1 Phase Cell Cycle Checkpoints; Humans; Kidney; Lipids; Male; Phosphorylation; Polycystic Kidney, Autosomal Dominant; PPAR gamma; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Renal Agents; Ribosomal Protein S6 Kinases, 70-kDa; Rosiglitazone; Signal Transduction; Sirolimus

2018
DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling.
    Investigational new drugs, 2010, Volume: 28, Issue:6

    Topics: Animals; Apoptosis; beta Catenin; Cell Line; Cell Proliferation; Cinnamates; Epithelial Cells; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Kidney; Mice; Phenylpropionates; Polycystic Kidney, Autosomal Dominant; PPAR gamma; Protein Processing, Post-Translational; Pyrimidines; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription, Genetic

2010
Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells.
    Basic & clinical pharmacology & toxicology, 2010, Volume: 106, Issue:6

    Topics: Apoptosis; Cell Line; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Epithelial Cells; G1 Phase; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; PPAR gamma; Resting Phase, Cell Cycle; Rosiglitazone; Thiazolidinediones; Time Factors

2010
Rosiglitazone inhibits transforming growth factor-β1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Cells, Cultured; Collagen Type I; Cysts; Enzyme Activation; Epithelial Cells; Female; Fibronectins; Fibrosis; Humans; Kidney Tubules; Male; MAP Kinase Signaling System; Middle Aged; Polycystic Kidney, Autosomal Dominant; PPAR gamma; RNA, Small Interfering; Rosiglitazone; Smad2 Protein; Thiazolidinediones; Time Factors; Transforming Growth Factor beta1

2011
Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone.
    American journal of physiology. Heart and circulatory physiology, 2013, Jan-01, Volume: 304, Issue:1

    Topics: Animals; Antioxidants; Arterioles; Calcium; Capillary Permeability; Cells, Cultured; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Genotype; Heterozygote; Hypertension; Male; Mesentery; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Myography; Nitric Oxide; Oxidative Stress; Peroxynitrous Acid; Phenotype; Polycystic Kidney, Autosomal Dominant; PPAR gamma; Renal Insufficiency; Reperfusion Injury; Rosiglitazone; Superoxides; Thiazolidinediones; Time Factors; TRPP Cation Channels; Vasodilation; Vasodilator Agents; Venules

2013